These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.

Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...

Weight-loss drugs are already dropping in price; could they go even lower? - Consumers are now able to pay roughly $500 for ...

He spotted the opportunity to invest in weight-loss drugs in 2023 before they exploded in 2024, and was an early AI mover, which he spied as a game changer in late 2022, early 2023. It's all about ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

How weight loss demand is draining Europe’s diabetes drug supply, as countries adopt varying speeds of approach to medicinal ...

Through nifty marketing and an insurance-circumventing subscription model that delivers medicine directly to your front door, ...

With headlines dominated by inflation concerns, recession fears, and tariff tensions, it is no surprise investors are feeling uneasy.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Regencell's stock soared 17,000% fueled by speculation, despite no revenue or clinical progress. Read why I think the RGC ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.